Clinical trial · Observational
Assessing Brain Metabolism Using MRS With Deuterated Glucose
Assessing Brain Metabolism Using 1H MRS With Deuterated Glucose
NCT06594315CI-TRIAL-00125254recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood Sample | Procedure | — | UNRESOLVED |
| Deuterated Glucose | Drug | — | UNRESOLVED |
| Magnetic Resonance Imaging (MRI) | Procedure | — | UNRESOLVED |
| MR spectroscopy (MRS) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Cohort 1: Healthy Controls
- description
- Twenty healthy controls for will have 2H-glucose metabolism in measured for development of robust strategy in optimizing acquisition parameters.
- interventionNames
- Drug: Deuterated Glucose
- Procedure: Magnetic Resonance Imaging (MRI)
- Procedure: Blood Sample
- Procedure: MR spectroscopy (MRS)
- label
- Cohort 2: Glioma participants (Single Time point)
- description
- Thirty participants with glioma who may or may not have received prior treatment for testing the optimized imaging protocol developed in Cohort 1.
- interventionNames
- Drug: Deuterated Glucose
- Procedure: Magnetic Resonance Imaging (MRI)
- Procedure: Blood Sample
- Procedure: MR spectroscopy (MRS)
- label
- Cohort 3: Glioma participants (Multiple Time points)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants must be \>= 18 years old * Cohort 1: Healthy controls * Cohort 2: Participants with histological proven glioma who have evidence of evaluable disease (with contrast enhancing lesion or non-enhancing lesion \> 4 cc) based on a prior MR scan. * Cohort 3: Participants with histologically proven glioma who will be undergoing any treatment. 2. Participants must not have any significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the subject's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent. 3. Participants must not be pregnant or breast-feeding. Persons of childbearing potential are required to obtain a negative serum or urine pregnancy test within 14 days of the scan. Effective contraception (men and women) must be used in subjects of childbearing potentials. 4. Participants must sign an informed consent indicating that they are aware of the investigational nature of the study Exclusion Criteria: Participants must be excluded from participating in this study if they are not able to comply with the study and/or follow-up procedures. 1. Participants exceeding the weight limitations of the scanner (300 pounds) 2. Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.) 3. Inability to complete the study due to other reasons (severe claustrophobia, MR incompatible medical implants or devices, inability to comply with pre-procedure fasting, etc.) 4. Pre-examination blood glucose level of \> 120 mg/dL as measured by point of care finger stick blood glucose test prior to MR examination. 5. Participants, either healthy volunteers (recruited for cohort 1) or participants with glioma (for cohorts 2 \&3), have history of diabetes mellitus.
References
Publications (0)
Data not yet available
No reference posted for this study.